Search Results

There are 7566768 results for: content related to: April 2013

  1. You have free access to this content
    Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    Reena Khanna, Jan C Preiss, John K MacDonald and Antje Timmer

    Published Online : 5 MAY 2015, DOI: 10.1002/14651858.CD007572.pub2

  2. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Version of Record online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  3. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  4. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  5. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL-12/23p40, in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 49, Issue 2, February 2009, Pages: 162–175, Dr Yaowei Zhu, Dr Chuanpu Hu, Dr Ming Lu, Dr Sam Liao, Dr Joseph C. Marini, Dr Jennifer Yohrling, Dr Newman Yeilding, Dr Hugh M. Davis and Dr Honghui Zhou

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270008329556

  6. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Version of Record online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  7. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    British Journal of Dermatology

    Volume 169, Issue 6, December 2013, Pages: 1295–1303, H.-Y. Chiu, C.-H. Chen, M.-S. Wu, Y.-P. Cheng and T.-F. Tsai

    Version of Record online : 2 DEC 2013, DOI: 10.1111/bjd.12461

  8. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases

    International Journal of Dermatology

    Volume 54, Issue 10, October 2015, Pages: 1194–1198, Naomi Takahashi, Shinji Noda, Takashi Taniguchi and Makoto Adachi

    Version of Record online : 27 MAY 2015, DOI: 10.1111/ijd.12859

  9. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

    Clinical and Experimental Dermatology

    Volume 39, Issue 6, August 2014, Pages: 696–707, Y. Meng, L. Dongmei, P. Yanbin, F. Jinju, T. Meile, L. Binzhu, H. Xiao, T. Ping and L. Jianmin

    Version of Record online : 14 JUL 2014, DOI: 10.1111/ced.12390

  10. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Version of Record online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  11. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis

    British Journal of Dermatology

    Volume 171, Issue 5, November 2014, Pages: 1181–1188, H.-Y. Chiu, T.-S. Wang, C.-C. Chan, Y.-P. Cheng, S.-J. Lin and T.-F. Tsai

    Version of Record online : 15 OCT 2014, DOI: 10.1111/bjd.13056

  12. Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis

    The Journal of Clinical Pharmacology

    Volume 50, Issue 3, March 2010, Pages: 257–267, Dr Honghui Zhou, Dr Chuanpu Hu, Dr Yaowei Zhu, Dr Ming Lu, Dr Sam Liao, Dr Newman Yeilding and Dr Hugh M. Davis

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009343695

  13. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-il-12/23p40 monoclonal antibody, during pregnancy and lactation

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 89, Issue 5, October 2010, Pages: 351–363, Pauline L. Martin, Clifford Sachs, Noritaka Imai, Hideshi Tsusaki, Satoru Oneda, Qun Jiao and George Treacy

    Version of Record online : 10 JUN 2010, DOI: 10.1002/bdrb.20250

  14. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 12, December 2014, Pages: 1633–1653, L. Puig, A. López, E. Vilarrasa and I. García

    Version of Record online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  15. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

    Experimental Dermatology

    Accepted manuscript online: 15 JUN 2016, Saakshi Khattri, Patrick M. Brunner, Sandra Garcet, Robert Finney, Steven R. Cohen, Margeaux Oliva, Riana Dutt, Judilyn Fuentes-Duculan, Xiuzhong Zheng, Xuan Li, Kathleen M. Bonifacio, Norma Kunjravia, Israel Coats, Inna Cueto, Patricia Gilleaudeau, Mary Sullivan-Whalen, Mayte Suárez-Fariñas, James G. Krueger and Emma Guttman-Yassky

    DOI: 10.1111/exd.13112

  16. You have free access to this content
    The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1145–1152, T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11142.x

  17. You have full text access to this OnlineOpen article
    Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up

    British Journal of Dermatology

    Volume 172, Issue 5, May 2015, Pages: 1371–1383, R.G. Langley, M. Lebwohl, G.G. Krueger, P.O. Szapary, Y. Wasfi, D. Chan, M.C. Hsu, Y. You, Y. Poulin, N. Korman, J.C. Prinz, K. Reich and on behalf of the PHOENIX 2 Investigators

    Version of Record online : 22 MAR 2015, DOI: 10.1111/bjd.13469

  18. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

    British Journal of Dermatology

    Volume 171, Issue 5, November 2014, Pages: 1189–1196, J.M.P.A. van den Reek, J. Zweegers, W. Kievit, M.E. Otero, P.P.M. van Lümig, R.J.B. Driessen, P.M. Ossenkoppele, M.D. Njoo, J.M. Mommers, M.I.A. Koetsier, W.P. Arnold, B.A.M. Sybrandy-Fleuren, A.L.A. Kuijpers, M.P.M. Andriessen, P.C.M. van de Kerkhof, M.M.B. Seyger and E.M.G.J. de Jong

    Version of Record online : 3 OCT 2014, DOI: 10.1111/bjd.13087

  19. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Version of Record online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  20. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

    British Journal of Dermatology

    Volume 172, Issue 1, January 2015, Pages: 244–252, R. Gniadecki, B. Bang, L.E. Bryld, L. Iversen, S. Lasthein and L. Skov

    Version of Record online : 30 NOV 2014, DOI: 10.1111/bjd.13343